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exhibits fusion of exon 4 of ETV6 with exon 14 of
NTRK3 (although fusion of exon 4 of ETV6 with exon
14 of NTRK3 has been reported in salivary gland
secretory carcinoma).4,9,13 In the few cases of secre-
tory carcinoma of the thyroid in which the fusion
breakpoints have been evaluated, the fusion has
involved exon 4 of ETV6 and exon 14 of NTRK3.2,3
Thus, these findings indicate that even in the presence
of an ETV6–NTRK3 fusion, other morphological fea-
tures to differentiate PTC from secretory carcinoma
must be considered; moreover, the clinical history
must be reviewed to ensure that the patient does not
have a salivary gland or breast primary.
In summary, we describe a case of primary secre-
tory carcinoma of the thyroid with increased prolifer-
ative activity and tumour necrosis. Differentiating
secretory carcinoma from PTC is crucial both for
prognostication and treatment purposes. Our patient
is currently being treated with concurrent chemother-
apy (taxol and carboplatin) and external beam radia-
tion; however, therapy with a pan-Trk inhibitor could
be considered in the future depending on the clinical
course of disease.
Ethics statement
The study has been performed according to the Decla-
ration of Helsinki. The procedures have been IRB-
approved (protocol no. 2016P001885). Informed
consent was not required for our study.
Conflict of interest
The authors have no conflicts of interest.
Elizabeth Y Wu1
Jasmin Lebastchi2
Ellen Marqusee2
Jochen H Lorch3
Jeffrey F Krane1
Justine A Barletta1
1Department of Pathology, Brigham and Women’s
Hospital, Harvard Medical School, 2Department of
Endocrinology, Brigham and Women’s Hospital, Harvard
Medical School, and 3Head and Neck Oncology Program,
Dana-Farber Cancer Institute, Boston, MA, USA
1. Dettloff J, Seethala RR, Stevens TM et al. Mammary analog
secretory carcinoma (MASC) involving the thyroid gland: a
report of the first 3 cases. Head Neck Pathol. 2017; 11; 124–130.
2. Dogan S, Wang L, Ptashkin RN et al. Mammary analog secre-
tory carcinoma of the thyroid gland: a primary thyroid
adenocarcinoma harboring ETV6–NTRK3 fusion. Mod. Pathol.
2016; 29; 985–995.
3. Reynolds S, Shaheen M, Olson G, Barry M, Wu J, Bocklage T.
A case of primary mammary analog secretory carcinoma
(MASC) of the thyroid masquerading as papillary thyroid carci-
noma: potentially more than a one off. Head Neck Pathol. 2016;
10; 405–413.
4. Skalova A, Vanecek T, Sima R et al. Mammary analogue secre-
tory carcinoma of salivary glands, containing the ETV6–
NTRK3 fusion gene: a hitherto undescribed salivary gland
tumor entity. Am. J. Surg. Pathol. 2010; 34; 599–608.
5. Stevens TM, Kovalovsky AO, Velosa C et al. Mammary analog
secretory carcinoma, low-grade salivary duct carcinoma, and
mimickers: a comparative study. Mod. Pathol. 2015; 28; 1084–
1100.
6. Rupp AP, Bocklage TJ. Mammary analog secretory carcinoma
of thyroid: a case report. Diagn. Cytopathol. 2017; 45; 45–50.
7. Skalova A, Bell D, Bishop JA et al. Secretory carcinoma. In
El-Naggar A, Chan J, Grandis J, Takata T, Slootweg P eds.
WHO classification of head and neck tumours (IARC WHO classifi-
cation of tumours). Geneva: Switzerland, 2017; 177–178.
8. Skalova A, Vanecek T, Majewska H et al. Mammary analogue
secretory carcinoma of salivary glands with high-grade trans-
formation: report of 3 cases with the ETV6–NTRK3 gene fusion
and analysis of TP53, beta-catenin, EGFR, and CCND1 genes.
Am. J. Surg. Pathol. 2014; 38; 23–33.
9. Leeman-Neill RJ, Kelly LM, Liu P et al. ETV6–NTRK3 is a com-
mon chromosomal rearrangement in radiation-associated thy-
roid cancer. Cancer 2014; 120; 799–807.
10. Volante M, Collini P, Nikiforov YE et al. Poorly differentiated
thyroid carcinoma: the Turin proposal for the use of uniform
diagnostic criteria and an algorithmic diagnostic approach.
Am. J. Surg. Pathol. 2007; 31; 1256–1264.
11. Hiltzik D, Carlson DL, Tuttle RM et al. Poorly differentiated thy-
roid carcinomas defined on the basis of mitosis and necrosis: a
clinicopathologic study of 58 patients. Cancer 2006; 106;
1286–1295.
12. Drilon A, Li G, Dogan S et al. What hides behind the MASC:
clinical response and acquired resistance to entrectinib after
ETV6–NTRK3 identification in a mammary analogue secretory
carcinoma (MASC). Ann. Oncol. 2016; 27; 920–926.
13. Skalova A, Vanecek T, Simpson RH et al. Mammary analogue
secretory carcinoma of salivary glands: molecular analysis of
25 ETV6 gene rearranged tumors with lack of detection of
classical ETV6–NTRK3 fusion transcript by standard RT–PCR:
report of 4 cases harboring ETV6-X gene fusion. Am. J. Surg.
Pathol. 2016; 40; 3–13.
14. Prasad ML, Vyas M, Horne MJ et al. Ntrk fusion oncogenes in
pediatric papillary thyroid carcinoma in northeast United
States. Cancer 2016; 122; 1097–1107.
Nephrogenic adenoma does not express
NKX3.1
DOI: 10.1111/his.13275
© 2017 John Wiley & Sons Ltd
Sir: Nephrogenic adenoma of the urinary tract is a
benign lesion that is associated frequently with
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urothelial injury or inflammation. It is reported in
virtually all urothelial lined sites, but is found most
commonly in the urinary bladder (75–80%) and the
urethra (12%), including the prostatic urethra.1,2
When identified in this latter site, it may be confused
with prostatic adenocarcinoma because of its pseudo-
infiltrative small gland-like pattern of growth. In
some cases, adjunctive immunohistochemical testing
may be needed to aid in this differential diagnostic
distinction. Previous studies have demonstrated that
the prostate cancer-associated marker a-methylacyl-
coenzyme A racemase (AMACR) is expressed in
35–100% of nephrogenic adenomas,3–6 and prostate-
specific antigen (PSA) and prostatic-specific acid phos-
phatase (PSAP) can be focally positive in 36% and
50%, respectively.2 Additionally, the commonly uti-
lized basal cell markers high-molecular weight cytok-
eratin (CK34bE12) and p63 may be negative in
nephrogenic adenoma.4 Although immunohistochem-
ical testing may provide invaluable ancillary
assistance, the expression of markers used frequently
in the evaluation of prostatic glandular lesions is
extremely heterogeneous in nephrogenic adenoma,
and a subset of cases may have complete immunohis-
tochemical overlap with prostatic adenocarcinoma.
NKX3.1 is a prostate-specific androgen-regulated
homeobox gene.7 Numerous studies have now docu-
mented that NKX3.1 immunohistochemistry can
serve as a highly sensitive and specific marker for
carcinomas of prostate epithelial origin.8–10 In many
diagnostic laboratories, NKX3.1 has become the pro-
static secretory epithelial marker of choice because of
its crisp nuclear pattern of immunoreactivity and
high sensitivity, even in high-grade tumours. To our
knowledge, an immunohistochemical analysis of
NKX3.1 has not been reported previously for nephro-
genic adenoma.
We selected 35 nephrogenic adenoma cases retro-
spectively, identified from the Pathology Departments
of the Cleveland Clinic and the University of
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Figure 2. A, Papillary pattern of a nephrogenic adenoma in the
prostatic urethra. B, No NKX3.1 immunoreactivity was present in
any of the 35 cases tested.
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Figure 1. A, Tubular pattern of nephrogenic adenoma in a transur-
ethral biopsy specimen. B, NKX3.1 immunohistochemistry demon-
strated no nuclear reactivity in the lesional cells.
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Michigan. All cases were reviewed to confirm diag-
noses and a single block was evaluated with NKX3.1
immunohistochemistry. We utilized the prediluted
rabbit polyclonal NKX3.1 antibody (1:50 dilution,
catalogue number CP422B; Biocare Medical, Con-
cord, CA, USA) on the Ventana Benchmark XT sys-
tem (Ventana Medical Systems, Tucson, AZ, USA)
with appropriate positive and negative controls. The
slides were pretreated with pretreatment solution
from Ventana at pH 7.5 for 40 min. Brown staining
for NKX3.1 protein expression was developed using
OptiView DAB polymer (Ventana Medical Systems),
with haematoxylin as a counterstain. Strong and dif-
fuse nuclear immunoreactivity was considered as a
positive reaction for NKX3.1, and prostatic adenocar-
cinoma and benign prostate glands were utilized as
positive internal and external controls. NKX3.1 was
non-reactive in all 35 of the nephrogenic adenoma
cases tested, regardless of specific histological pattern
(Figures 1 and 2).
In conclusion, in our series of 35 nephrogenic ade-
nomas, NKX3.1 expression was completely absent.
This suggests that, unlike other immunohistochemi-
cal antibodies used as surrogates of prostatic secre-
tory lineage, NKX3.1 has potential utility as a
prostate specific marker in the differential diagnostic
distinction between nephrogenic adenoma and pro-
static adenocarcinoma.
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